Bli medlem
Bli medlem

Du är här

2014-08-12

Diamyd Medical AB: Diamyd Medical reinforces focus on business development

Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) informs that
its lead candidate therapeutic Diamyd® for treatment and prevention
of type 1 diabetes experiences an increased interest. Consensus is
that the disease must be attacked by inducing tolerance to beta cell
auto-antigens at a time when the inflammatory components of the
immune system are kept at bay. Diamyd® is the furthest developed beta
cell specific auto-antigen (GAD65 formulated in alum) available and
the Company is currently in discussion with half a dozen parties
about new combination studies. Diamyd Medical is therefore preparing
to meet this increased interest by reinforcing its focus on business
development.

"We are pleased with the way the interest for Diamyd® is developing,"
says Peter Zerhouni, President and CEO of Diamyd Medical.
"Strategically, our business development resources will be focused on
two main interests; the Diamyd® diabetes vaccine and our new interest
in Personalized Regenerative Medicine, in particular for the
treatment of diabetes. To make available further management resources
for this, the Board has asked the Company Chairman, Anders
Essen-Möller, to assume responsibility for Diamyd Medical's external
communication, with the aim of meeting the interest from potential
partners and other stakeholders. Anders Essen-Möller has a documented
and successful experience in leading organizations to high-level
deals."

Type 1 diabetes is an autoimmune disease where the immune system
attacks the patients' own insulin producing beta cells. For these
patients, daily treatment with insulin is mandatory to sustain life.
The importance of finding a cure is high for the world's health care
systems and the well-being of patients. The annual market for an easy
to use, successful therapeutic is estimated to several billion
dollars.

About Diamyd®
Diamyd® is a therapeutic under development for the treatment and
prevention of autoimmune diabetes. Diamyd® has been used in trials
totaling more than one thousand patients with an excellent safety
profile. Diamyd has shown an overall 16% efficacy (p=0.1) in a
European Phase III trial and is currently being further developed in
combination regimens with other therapeutic compounds. Diamyd® is
easy to administer in any clinical setting.

For further information, please contact:
Anders Essen-Möller, Chairman Diamyd Medical AB
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com

About Diamyd Medical
Diamyd Medical is dedicated to fight type 1 diabetes and to work
towards a cure for the disease. Diamyd Medical's current projects
include development of combination regimens for arresting the
successive destruction of insulin producing beta cells using the
Company's GAD65-based diabetes vaccine, such as for example Diamyd®+
Vitamin D with or without an anti-inflammatory compound; and Diamyd®+
GABA, for which Diamyd Medical licenses exclusive intellectual rights
from the University of California in Los Angeles (UCLA). Diamyd
Medical has further acquired 46% of the stem cell company Cellaviva
AB that is establishing a Swedish commercial bank for private family
saving of umbilical cord blood and other sources of stem cells. Stem
cells are required for Personalized Regenerative Medicine (PRM), for
example to restore beta cell mass in diabetes patients where
autoimmunity has been arrested.

Remium Nordic AB is the Company's Certified Adviser.

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26,
Fax: +46 8 661 63 68

E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website:
www.diamyd.com.

-----------------------------------------------------------
http://news.cision.com/diamyd-medical-ab/r/diamyd-medical-reinforces-foc...
http://mb.cision.com/Main/6746/9626642/273691.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.